Jiaoyang Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiaoyang Cai has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Ching-Hon Pui
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
8 shared publications Ningling Wang
10Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Hefei, China
8 shared publicationsChangda Liang
14Department of Hematology/Oncology, Jiangxi Provincial Children's Hospital, Nanchang, China
7 shared publicationsJingyan Tang
Department of Hematology/Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, National Health Committee Key Laboratory of Pediatric Hematology and Oncology, Shanghai, China
7 shared publicationsShuhong Shen
Department of Hematology/Oncology Shanghai Children's Medical Center, Shanghai Jiao Tong University of School of Medicine Shanghai China
7 shared publicationsXin Tian
18Department of Hematology/Oncology, KunMing Children’s Hospital, Kunming, China
7 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in BMC Pediatrics
Common SAEs and their impact on the prognosis of children treated with the CCCG-ALL-2015 protocol: a retrospective multicentre Chinese study
- 17 September 2026
- Published by Springer Nature in BMC Pediatrics
Open AccessCommon SAEs and their impact on the prognosis of children treated with the CCCG-ALL-2015 protocol: a retrospective multicentre Chinese study
- 13 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (20) , 2417-2427
Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL
Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or discontinuation. This study aimed to identify AAP risk factors, assess outcomes after first and second episodes, and evaluate the impact of asparaginase rechallenge. We retrospectively analyzed 7640 patients (aged 1 month to 18 years) treated under the Chinese Children Cancer Group ALL 2015 protocol. Patients were stratified as low risk (LR), intermediate risk (IR), or high risk (HR) based on clinical features and measurable residual disease (MRD). AAP was categorized as early or late onset depending on treatment phase. Older age and IR/HR status were independent risk factors for AAP. The cumulative AAP incidence was 2.2% in LR and 5.8% in IR/HR groups. Among 298 patients who developed AAP, 92 were rechallenged with asparaginase; second episodes occurred in 20.8% of LR and 33.8% of IR/HR patients, with no increase in severity. Lack of rechallenge and day 46 MRD of ≥0.01% were independently associated with inferior event-free survival (EFS). Among patients with early-onset AAP, those who were rechallenged had superior 5-year EFS than those who were not rechallenged (80.1% vs 60.2%; P = .003). Similarly, among IR/HR group, those who were rechallenged had better 5-year EFS than those who were not rechallenged (82.4% vs 60.6%; P = .004). IR/HR patients with early-onset AAP who were not rechallenged had especially poor outcomes (5-year EFS, 53.3%). These findings support considering asparaginase rechallenge in IR/HR patients with early-onset AAP when alternative therapies are limited. This trial was registered at www.chictr.org.cn as #ChiCTR2000032211.
- 13 November 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (20) , 2417-2427
Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL
Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or discontinuation. This study aimed to identify AAP risk factors, assess outcomes after first and second episodes, and evaluate the impact of asparaginase rechallenge. We retrospectively analyzed 7640 patients (aged 1 month to 18 years) treated under the Chinese Children Cancer Group ALL 2015 protocol. Patients were stratified as low risk (LR), intermediate risk (IR), or high risk (HR) based on clinical features and measurable residual disease (MRD). AAP was categorized as early or late onset depending on treatment phase. Older age and IR/HR status were independent risk factors for AAP. The cumulative AAP incidence was 2.2% in LR and 5.8% in IR/HR groups. Among 298 patients who developed AAP, 92 were rechallenged with asparaginase; second episodes occurred in 20.8% of LR and 33.8% of IR/HR patients, with no increase in severity. Lack of rechallenge and day 46 MRD of ≥0.01% were independently associated with inferior event-free survival (EFS). Among patients with early-onset AAP, those who were rechallenged had superior 5-year EFS than those who were not rechallenged (80.1% vs 60.2%; P = .003). Similarly, among IR/HR group, those who were rechallenged had better 5-year EFS than those who were not rechallenged (82.4% vs 60.6%; P = .004). IR/HR patients with early-onset AAP who were not rechallenged had especially poor outcomes (5-year EFS, 53.3%). These findings support considering asparaginase rechallenge in IR/HR patients with early-onset AAP when alternative therapies are limited. This trial was registered at www.chictr.org.cn as #ChiCTR2000032211.
- Open Access
- 30 October 2025
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 21 (12) , 1204-1217
Expert consensus on disease-based long-term follow-up care plans for childhood cancer survivors
Background: Childhood cancer survivors (CCSs) are at increased risk of long-term treatment-related complications. Although international guidelines support risk-based long-term follow-up (LTFU) care, its standardized implementation in China has been limited. To address this gap, the National Children’s Medical Center–Shanghai convened a multidisciplinary expert panel to develop disease-based LTFU care plans tailored to the Chinese healthcare context. Methods: Guided by established international frameworks (Children’s Oncology Group, International Guideline Harmonization Group, and PanCareFollowUp), an expert group representing 25 institutions across China developed consensus-based LTFU care plans for common pediatric cancer patients and post-hematopoietic cell transplant survivors. Each care plan includes core components: a treatment summary, risk stratification for late effects, recommended surveillance, psychosocial evaluation, and lifestyle guidance. The panel also developed a consensus on the specific roles of oncologists, primary care providers, and subspecialists. Results: Finalized care plans provide structured, risk-adapted follow-up pathways for CCSs. The model emphasizes multidisciplinary collaboration, clinical feasibility, and scalability across diverse settings. As part of the care process, a centralized survivorship database has been integrated to facilitate clinical use and data collection. This system supports the generation of standardized treatment summaries and longitudinal documentation of late effects across the continuum of survivorship care. Tools, such as clinician checklists and survivor education templates, were also developed to support clinical use and promote consistency across institutions. A list of outcome metrics was proposed to evaluate the implementation outcomes of this initiative. Conclusions: This expert consensus establishes an innovative, nationally coordinated, disease-specific LTFU care framework for CCSs in China. This study provides a practical foundation for improving survivorship care quality and guiding clinical practice nationwide. This model can serve as a blueprint for other low- and middle-income countries seeking to strengthen LTFU care for CCSs. Graphical
- 30 October 2025
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 21 (12) , 1204-1217
Open AccessExpert consensus on disease-based long-term follow-up care plans for childhood cancer survivors
Background: Childhood cancer survivors (CCSs) are at increased risk of long-term treatment-related complications. Although international guidelines support risk-based long-term follow-up (LTFU) care, its standardized implementation in China has been limited. To address this gap, the National Children’s Medical Center–Shanghai convened a multidisciplinary expert panel to develop disease-based LTFU care plans tailored to the Chinese healthcare context. Methods: Guided by established international frameworks (Children’s Oncology Group, International Guideline Harmonization Group, and PanCareFollowUp), an expert group representing 25 institutions across China developed consensus-based LTFU care plans for common pediatric cancer patients and post-hematopoietic cell transplant survivors. Each care plan includes core components: a treatment summary, risk stratification for late effects, recommended surveillance, psychosocial evaluation, and lifestyle guidance. The panel also developed a consensus on the specific roles of oncologists, primary care providers, and subspecialists. Results: Finalized care plans provide structured, risk-adapted follow-up pathways for CCSs. The model emphasizes multidisciplinary collaboration, clinical feasibility, and scalability across diverse settings. As part of the care process, a centralized survivorship database has been integrated to facilitate clinical use and data collection. This system supports the generation of standardized treatment summaries and longitudinal documentation of late effects across the continuum of survivorship care. Tools, such as clinician checklists and survivor education templates, were also developed to support clinical use and promote consistency across institutions. A list of outcome metrics was proposed to evaluate the implementation outcomes of this initiative. Conclusions: This expert consensus establishes an innovative, nationally coordinated, disease-specific LTFU care framework for CCSs in China. This study provides a practical foundation for improving survivorship care quality and guiding clinical practice nationwide. This model can serve as a blueprint for other low- and middle-income countries seeking to strengthen LTFU care for CCSs. Graphical
- Open Access
- 21 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (16) , e71090
A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG‐ALL‐2015
Objective: Acute abdomen presents a significant challenge in the treatment of childhood acute lymphoblastic leukemia (ALL), potentially leading to treatment failure and treatment‐related mortality. Results from the multicenter study of CCCG‐ALL‐2015 showed significant improvements in overall survival (OS) and event‐free survival (EFS) for childhood ALL. However, the primary aim of this study was to determine the incidence, risk factors, and clinical impact of acute abdomen in the CCCG‐ALL‐2015 protocol, with the ultimate goal in the future of establishing evidence‐based preventive strategies to reduce its occurrence.Methods: Patients participating in the CCCG‐ALL‐2015 protocol from January 1, 2015, to December 31, 2019, were included in this analysis. The occurrence of acute abdomen in 7640 patients with ALL was analyzed retrospectively. The data was collected in August 2023 from the Data Center. Acute abdomen analyzed in this study included: acute pancreatitis, acute appendicitis, ileus, enterobrosis, enterorrhagia, peritonitis, enteritis, and others (urinary calculus, anaphylactoid purpura, cholecystitis). The clinical data of patients with acute abdomen were extracted from the database and analyzed.Results: A total of 7640 patients were recruited in the study, and 512 (6.7%) patients diagnosed with acute abdomen were identified. Of the 512 patients, 50 patients experienced two episodes of acute abdomen, 5 patients had three episodes, and 2 patients had four episodes. Among different types of acute abdomen, the incidence of acute pancreatitis was the highest (4.0%), followed by ileus (1.2%) and acute appendicitis (0.7%). There was no difference in the incidence of acute abdomen between males and females (6.6% vs. 6.9%, p = 0.64). The incidence of acute abdomen was associated with age, and patients older than 10 years had a significantly higher incidence rate than those less than 1 year and 1–10 years old (13.0% vs. 5.7%, p < 0.0001). The incidence rate of enterorrhagia was significantly higher in patients less than 1 year and older than 10 years than that in patients aged 1–10 years old (1.4% vs. 0.4%, p < 0.0001). The incidence of acute abdomen in the intermediate or high‐risk (I/HR) group was higher than that in the low‐risk (LR) group (9.9% vs. 3.7%, p < 0.001). Acute abdomen mainly occurred in the induction remission phase (57.3%) and the continuation and reinduction phase (39.3%). A total of 16 patients died from acute abdomen, including four patients in the LR group and 12 patients in the I/HR group. Among the different types of acute abdomen, the mortality rate of enterorrhagia was the highest (16.7%), followed by enterobrosis (9.1%).Conclusion: This multicenter study investigates the frequency, risk factors, and impact of acute abdomen in the CCCG‐ALL‐2015 protocol, the largest pediatric ALL study in China. We identified acute abdomen in 6.7% of patients, with the highest incidence during the induction remission phase and in older children and those with intermediate or high‐risk ALL. Acute pancreatitis was the most common type, while enterorrhagia had the highest mortality. These findings underscore the need for heightened vigilance and proactive management of acute abdomen to improve outcomes in children with ALL.Trial Registration: Chinese Clinical Trial Registry: ChiCTR‐IPR‐14005706
- 21 August 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (16) , e71090
Open AccessA Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG‐ALL‐2015
Objective: Acute abdomen presents a significant challenge in the treatment of childhood acute lymphoblastic leukemia (ALL), potentially leading to treatment failure and treatment‐related mortality. Results from the multicenter study of CCCG‐ALL‐2015 showed significant improvements in overall survival (OS) and event‐free survival (EFS) for childhood ALL. However, the primary aim of this study was to determine the incidence, risk factors, and clinical impact of acute abdomen in the CCCG‐ALL‐2015 protocol, with the ultimate goal in the future of establishing evidence‐based preventive strategies to reduce its occurrence.Methods: Patients participating in the CCCG‐ALL‐2015 protocol from January 1, 2015, to December 31, 2019, were included in this analysis. The occurrence of acute abdomen in 7640 patients with ALL was analyzed retrospectively. The data was collected in August 2023 from the Data Center. Acute abdomen analyzed in this study included: acute pancreatitis, acute appendicitis, ileus, enterobrosis, enterorrhagia, peritonitis, enteritis, and others (urinary calculus, anaphylactoid purpura, cholecystitis). The clinical data of patients with acute abdomen were extracted from the database and analyzed.Results: A total of 7640 patients were recruited in the study, and 512 (6.7%) patients diagnosed with acute abdomen were identified. Of the 512 patients, 50 patients experienced two episodes of acute abdomen, 5 patients had three episodes, and 2 patients had four episodes. Among different types of acute abdomen, the incidence of acute pancreatitis was the highest (4.0%), followed by ileus (1.2%) and acute appendicitis (0.7%). There was no difference in the incidence of acute abdomen between males and females (6.6% vs. 6.9%, p = 0.64). The incidence of acute abdomen was associated with age, and patients older than 10 years had a significantly higher incidence rate than those less than 1 year and 1–10 years old (13.0% vs. 5.7%, p < 0.0001). The incidence rate of enterorrhagia was significantly higher in patients less than 1 year and older than 10 years than that in patients aged 1–10 years old (1.4% vs. 0.4%, p < 0.0001). The incidence of acute abdomen in the intermediate or high‐risk (I/HR) group was higher than that in the low‐risk (LR) group (9.9% vs. 3.7%, p < 0.001). Acute abdomen mainly occurred in the induction remission phase (57.3%) and the continuation and reinduction phase (39.3%). A total of 16 patients died from acute abdomen, including four patients in the LR group and 12 patients in the I/HR group. Among the different types of acute abdomen, the mortality rate of enterorrhagia was the highest (16.7%), followed by enterobrosis (9.1%).Conclusion: This multicenter study investigates the frequency, risk factors, and impact of acute abdomen in the CCCG‐ALL‐2015 protocol, the largest pediatric ALL study in China. We identified acute abdomen in 6.7% of patients, with the highest incidence during the induction remission phase and in older children and those with intermediate or high‐risk ALL. Acute pancreatitis was the most common type, while enterorrhagia had the highest mortality. These findings underscore the need for heightened vigilance and proactive management of acute abdomen to improve outcomes in children with ALL.Trial Registration: Chinese Clinical Trial Registry: ChiCTR‐IPR‐14005706
- 24 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (17) , 1890-1902
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL
We evaluated the prognostic and therapeutic significance of measurable residual disease (MRD) during remission induction in pediatric patients with acute lymphoblastic leukemia (ALL). In the Chinese Children Cancer Group ALL 2015 protocol, 7640 patients were categorized into low-, intermediate-, or high-risk groups based on clinical and genetic features. Final risk classification was determined by assessing MRD using flow cytometry on days 19 and 46 of remission induction with additional intensified chemotherapy for day 19 MRD ≥1%. Patients with B-ALL with negative MRD (<0.01%) on day 19 or day 46 had significantly better 5-year event-free survival (EFS) than those with MRD of between 0.01% and 0.99% who, in turn, had better EFS than patients with MRD of ≥1%. Provisional low-risk patients with day 19 MRD ≥1% but negative day 46 MRD who were reclassified as intermediate risk had a 5-year EFS that was comparable with that of low-risk patients with day 19 MRD of 0.3% to 0.99% and negative day 46 MRD (82.5% vs 83.0%) and better EFS than provisional low-risk patients with MRD on both days (83.0% vs 72.6%; P < .001). Similarly, patients with provisional intermediate-risk B-ALL with day 19 MRD ≥1% but negative day 46 MRD who received additional therapy had better 5-year EFS than those with day 19 MRD between 0.3% and 0.99% (70.7% vs 53.0%; P < .001). Among low-risk patients with negative day 46 MRD, those with negative day 19 MRD had superior EFS than those with positive day 19 MRD (91.7% vs 86.1%; P < .001). Optimal use of day 19 MRD could improve individualized treatment and outcomes. This trial was registered at www.chictr.org.cn as #ChiCTR-IPR-14005706.
- 24 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (17) , 1890-1902
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL
We evaluated the prognostic and therapeutic significance of measurable residual disease (MRD) during remission induction in pediatric patients with acute lymphoblastic leukemia (ALL). In the Chinese Children Cancer Group ALL 2015 protocol, 7640 patients were categorized into low-, intermediate-, or high-risk groups based on clinical and genetic features. Final risk classification was determined by assessing MRD using flow cytometry on days 19 and 46 of remission induction with additional intensified chemotherapy for day 19 MRD ≥1%. Patients with B-ALL with negative MRD (<0.01%) on day 19 or day 46 had significantly better 5-year event-free survival (EFS) than those with MRD of between 0.01% and 0.99% who, in turn, had better EFS than patients with MRD of ≥1%. Provisional low-risk patients with day 19 MRD ≥1% but negative day 46 MRD who were reclassified as intermediate risk had a 5-year EFS that was comparable with that of low-risk patients with day 19 MRD of 0.3% to 0.99% and negative day 46 MRD (82.5% vs 83.0%) and better EFS than provisional low-risk patients with MRD on both days (83.0% vs 72.6%; P < .001). Similarly, patients with provisional intermediate-risk B-ALL with day 19 MRD ≥1% but negative day 46 MRD who received additional therapy had better 5-year EFS than those with day 19 MRD between 0.3% and 0.99% (70.7% vs 53.0%; P < .001). Among low-risk patients with negative day 46 MRD, those with negative day 19 MRD had superior EFS than those with positive day 19 MRD (91.7% vs 86.1%; P < .001). Optimal use of day 19 MRD could improve individualized treatment and outcomes. This trial was registered at www.chictr.org.cn as #ChiCTR-IPR-14005706.
- 7 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (3) , e31529
Parental Acceptance of Human Papillomavirus Vaccination Among Females Treated for Childhood Cancer and/or With Hematopoietic Stem Cell Transplantation: A Cross‐Sectional Study
Background: Survivors of childhood cancer (CCS) and hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of human papillomavirus (HPV)‐associated malignancies. Although HPV vaccination is recommended for these groups, parental acceptance remains uncertain.Procedure: We recruited caregivers of female CCS/HSCT aged ≥9 years from the Shanghai Children's Medical Center (SCMC) vaccination clinic. Caregivers of females who were at least 6 months post treatment, off immunosuppressants, and disease‐free were eligible. Caregivers completed a questionnaire assessing demographics, HPV knowledge, and their willingness to vaccinate their daughters.Results: Of the 219 caregivers enrolled, 195 (89.0%) completed the survey. Among the children of caregivers who responded, 44.6% (87/195) had undergone HSCT. All respondent caregivers lacked awareness that the HPV vaccine was recommended for their daughters. Willingness to vaccinate was endorsed by 65.1% (127/195) of caregivers, and was significantly associated with a household income over ¥50,000 (p = 0.02), the mother's HPV vaccination status (p < 0.001), and their daughter receiving any vaccination post therapy (p = 0.02). The most common reasons for vaccine refusal included concerns about its impact on the child's primary disease (64.7%, 44/68), vaccine safety (58.8%, 40/68), and the belief that their child was too young for HPV vaccination (50.0%, 34/68). Only 15 of the 127 (11.8%) caregivers who initially expressed willingness to vaccinate their children had actually initiated vaccination.Conclusion: A substantial minority of Chinese caregivers of female CCS/HSCT are hesitant to vaccinate their daughters against HPV. Addressing caregivers’ knowledge deficits and misperceptions about vaccine safety and barriers to accessing HPV vaccination is important to improve uptake.
- 7 January 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (3) , e31529
Parental Acceptance of Human Papillomavirus Vaccination Among Females Treated for Childhood Cancer and/or With Hematopoietic Stem Cell Transplantation: A Cross‐Sectional Study
Background: Survivors of childhood cancer (CCS) and hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of human papillomavirus (HPV)‐associated malignancies. Although HPV vaccination is recommended for these groups, parental acceptance remains uncertain.Procedure: We recruited caregivers of female CCS/HSCT aged ≥9 years from the Shanghai Children's Medical Center (SCMC) vaccination clinic. Caregivers of females who were at least 6 months post treatment, off immunosuppressants, and disease‐free were eligible. Caregivers completed a questionnaire assessing demographics, HPV knowledge, and their willingness to vaccinate their daughters.Results: Of the 219 caregivers enrolled, 195 (89.0%) completed the survey. Among the children of caregivers who responded, 44.6% (87/195) had undergone HSCT. All respondent caregivers lacked awareness that the HPV vaccine was recommended for their daughters. Willingness to vaccinate was endorsed by 65.1% (127/195) of caregivers, and was significantly associated with a household income over ¥50,000 (p = 0.02), the mother's HPV vaccination status (p < 0.001), and their daughter receiving any vaccination post therapy (p = 0.02). The most common reasons for vaccine refusal included concerns about its impact on the child's primary disease (64.7%, 44/68), vaccine safety (58.8%, 40/68), and the belief that their child was too young for HPV vaccination (50.0%, 34/68). Only 15 of the 127 (11.8%) caregivers who initially expressed willingness to vaccinate their children had actually initiated vaccination.Conclusion: A substantial minority of Chinese caregivers of female CCS/HSCT are hesitant to vaccinate their daughters against HPV. Addressing caregivers’ knowledge deficits and misperceptions about vaccine safety and barriers to accessing HPV vaccination is important to improve uptake.
- 3 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1354-1366
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study
Summary: This study delivers a comprehensive evaluation of the efficacy and pharmacokinetics of high‐dose methotrexate (HDMTX) in a large cohort of Chinese paediatric acute lymphoblastic leukaemia patients. A total of 533 patients were included in the prognostic analysis. An association was observed between lower steady‐state MTX concentrations (MLL rearrangements. In contrast, such an association did not emerge within the low‐risk patient group. Additionally, utilizing population pharmacokinetic modelling (6051 concentrations from 815 patients), we identified the significant impact of physiological maturation, estimated glomerular filtration rate, sex and concurrent dasatinib administration on MTX pharmacokinetics. Simulation‐based recommendations include a reduced dosage regimen for those with renal insufficiency and a specific 200 mg/kg dosage for infants under 1 year. The findings underscore the critical role of HDMTX in treating IR/HR populations and call for a reassessment of its application in lower‐risk groups. An individualized pharmacokinetic dosage regimen could achieve the most optimal results, ensuring the largest proportion of steady‐state concentrations within the optimal range.
- 3 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (4) , 1354-1366
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study
Summary: This study delivers a comprehensive evaluation of the efficacy and pharmacokinetics of high‐dose methotrexate (HDMTX) in a large cohort of Chinese paediatric acute lymphoblastic leukaemia patients. A total of 533 patients were included in the prognostic analysis. An association was observed between lower steady‐state MTX concentrations (MLL rearrangements. In contrast, such an association did not emerge within the low‐risk patient group. Additionally, utilizing population pharmacokinetic modelling (6051 concentrations from 815 patients), we identified the significant impact of physiological maturation, estimated glomerular filtration rate, sex and concurrent dasatinib administration on MTX pharmacokinetics. Simulation‐based recommendations include a reduced dosage regimen for those with renal insufficiency and a specific 200 mg/kg dosage for infants under 1 year. The findings underscore the critical role of HDMTX in treating IR/HR populations and call for a reassessment of its application in lower‐risk groups. An individualized pharmacokinetic dosage regimen could achieve the most optimal results, ensuring the largest proportion of steady‐state concentrations within the optimal range.
- Open Access
- 1 March 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300331
Care Models and Barriers to Long-Term Follow-Up Care Among Childhood Cancer Survivors and Health Care Providers in Asia: A Literature Review
Most available data evaluating childhood cancer survivorship care focus on the experiences of high-income Western countries, whereas data from Asian countries are limited. To address this knowledge deficit, we aimed to characterize survivorship care models and barriers to participation in long-term follow-up (LTFU) care among childhood cancer survivors (CCSs) and health care providers in Asian countries. Twenty-four studies were identified. Most institutions in China and Turkey adopt the oncology specialist care model, whereas in Japan, India, Singapore, and South Korea, after completion of therapy LTFU programs are available in some institutions. In terms of survivor barriers, findings highlight the need for comprehensive age-appropriate education and support and personalized approaches in addressing individual preferences and challenges during survivorship. Health care professionals need education about potential late effects of cancer treatment, recommended guidance for health surveillance and follow-up care, and their role in facilitating the transition from pediatric to adult-focused care. To optimize the delivery of cancer survivorship care, efforts are needed to increase patient and family awareness about the purpose and potential benefits of LTFU care, improve provider education and training, and promote policy change to ensure that CCSs have access to essential services and resources to optimize quality of survival.
- 1 March 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300331
Open AccessCare Models and Barriers to Long-Term Follow-Up Care Among Childhood Cancer Survivors and Health Care Providers in Asia: A Literature Review
Most available data evaluating childhood cancer survivorship care focus on the experiences of high-income Western countries, whereas data from Asian countries are limited. To address this knowledge deficit, we aimed to characterize survivorship care models and barriers to participation in long-term follow-up (LTFU) care among childhood cancer survivors (CCSs) and health care providers in Asian countries. Twenty-four studies were identified. Most institutions in China and Turkey adopt the oncology specialist care model, whereas in Japan, India, Singapore, and South Korea, after completion of therapy LTFU programs are available in some institutions. In terms of survivor barriers, findings highlight the need for comprehensive age-appropriate education and support and personalized approaches in addressing individual preferences and challenges during survivorship. Health care professionals need education about potential late effects of cancer treatment, recommended guidance for health surveillance and follow-up care, and their role in facilitating the transition from pediatric to adult-focused care. To optimize the delivery of cancer survivorship care, efforts are needed to increase patient and family awareness about the purpose and potential benefits of LTFU care, improve provider education and training, and promote policy change to ensure that CCSs have access to essential services and resources to optimize quality of survival.
- Open Access
- 10 June 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 38, 100818
Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome–positive acute lymphoblastic leukemia: a case–control study
- 10 June 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 38, 100818
Open AccessEffect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome–positive acute lymphoblastic leukemia: a case–control study
- Top Cited Papers
- 20 March 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (9) , 1670-1683
Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
PURPOSE: We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS: This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose. After interim analysis of the first 30 patients treated (27 at the recommended dose) showing that the treatment was safe and effective, the study enrolled additional patients according to the study design. RESULTS: Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. Their overall 12-month event-free survival (EFS) was 73.5% (95% CI, 67.3 to 80.3). Relapse occurred in 43 patients (24 with CD19+/CD22+ relapse, 16 CD19–/CD22+, one CD19–/CD22–, and two unknown). Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. The 12-month EFS was 85.0% (95% CI, 77.2 to 93.6) for the 78 patients treated with transplantation and 69.2% (95% CI, 60.8 to 78.8) for the 116 nontransplanted patients ( P = .03, time-dependent covariate Cox model). All 25 patients with persistent B-cell aplasia at 6 months remained in remission at 12 months. The 12-month EFS for the 20 patients with isolated testicular relapse was 95.0% (95% CI, 85.9 to 100), and for the 10 patients with isolated CNS relapse, it was 68.6% (95% CI, 44.5 to 100). Cytokine release syndrome developed in 198 (88.0%) patients, and CAR T-cell neurotoxicity in 47 (20.9%), resulting in three deaths. CONCLUSION: CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse. [Media: see text]
- 20 March 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (9) , 1670-1683
Top Cited PapersCoadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
PURPOSE: We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS: This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose. After interim analysis of the first 30 patients treated (27 at the recommended dose) showing that the treatment was safe and effective, the study enrolled additional patients according to the study design. RESULTS: Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. Their overall 12-month event-free survival (EFS) was 73.5% (95% CI, 67.3 to 80.3). Relapse occurred in 43 patients (24 with CD19+/CD22+ relapse, 16 CD19–/CD22+, one CD19–/CD22–, and two unknown). Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. The 12-month EFS was 85.0% (95% CI, 77.2 to 93.6) for the 78 patients treated with transplantation and 69.2% (95% CI, 60.8 to 78.8) for the 116 nontransplanted patients ( P = .03, time-dependent covariate Cox model). All 25 patients with persistent B-cell aplasia at 6 months remained in remission at 12 months. The 12-month EFS for the 20 patients with isolated testicular relapse was 95.0% (95% CI, 85.9 to 100), and for the 10 patients with isolated CNS relapse, it was 68.6% (95% CI, 44.5 to 100). Cytokine release syndrome developed in 198 (88.0%) patients, and CAR T-cell neurotoxicity in 47 (20.9%), resulting in three deaths. CONCLUSION: CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse. [Media: see text]